Private Capital Update from China

China’s economy has returned to growth in post-COVID-19 recovery, and the government is looking to harness renewed investor sentiment with regulatory updates designed to further open financial markets to international capital. Mainland Chinese regulators have approved updates to the Qualified Foreign Investor (QFI) program, streamlining the application process and… Read More

Matrix and Efung Lead USD135m Series E for Chinese Drug Developer Biostar

Matrix Partners China and Efung Capital led a CNY890m (approximately USD135m) Series E for Beijing Biostar Technologies, a China-based developer of anti-tumor, small-molecule chemical drugs, with participation from CCB International Capital, Sinopharma-CICC Capital, Tianjin Venture Capital Management, and Chengdu Tianfu International Bio-Town Investment & Development. Read more… Read More



(default archive template)